REFERENCES
1.
Tisher CC, Madsen KM: Anatomy of the kidney. In
Brenner BM (ed): Brenner & Rector's The Kidney, 6th ed. Philadelphia, WB Saunders,
2000, pp 3–67.
2.
Stanton BA, Koeppen BM: Elements of renal function.
In Berne RM, Levy MN (eds): Physiology, 4th ed.
St Louis, CV Mosby, 1998, pp 677–698.
3.
Maddox DA, Brenner BM: Glomerular ultrafiltration.
In Brenner BM (ed): Brenner & Rector's The
Kidney, 6th ed. Philadelphia, WB Saunders, 2000, pp 319–374.
4.
Thurau K, Boylan JW: Acute renal success: The
unexpected logic of oliguria in acute renal failure. Am J Med 61:308–315,
1976.
5.
Shipley RE, Study RS: Changes in renal blood flow,
extraction of inulin, glomerular filtration rate, tissue pressure and urine flow
with acute alterations of renal artery pressure. Am J Physiol 167:676–688,
1951.
6.
Aukland K, Oien AH: Renal autoregulation: Models
combining tubuloglomerular feedback and myogenic response. Am J Physiol 252:F768–F783,
1987.
7.
Desjars PH, Pinaud M, Bugnon D, et al: Norepinephrine
has no deleterious renal effects in human septic shock. Crit Care Med 17:426–429,
1989.
8.
Kelleher SP, Robinette JB, Miller F, Conger JD:
Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure.
Kidney Int 31:725–730, 1987.
9.
Mackay JH, Feerick AE, Woodson LC, et al: Increasing
organ blood flow during cardiopulmonary bypass in pigs: Comparison of dopamine and
perfusion pressure. Crit Care Med 23:1090–1098, 1995.
10.
Brezis M, Rosen S: Hypoxia of the renal medulla—its
implications for disease. N Engl J Med 332:647–655, 1995.
11.
Kasiske BL, Keane WF: Laboratory assessment of
renal disease: Clearance, urinalysis and renal biopsy. In
Brenner BM (ed): Brenner & Rector's The Kidney, 6th ed. Philadelphia, WB Saunders,
2000, pp 1129–1170.
12.
Tobias GJ, McLaughlin RF, Hopper J: Endogenous
creatinine clearance: A valuable clinical test of glomerular filtration and a prognostic
guide in chronic renal disease. N Engl J Med 266:317–323, 1962.
13.
Sladen RN, Endo E, Harrison T: Two-hour versus
22-hour creatinine clearance in critically ill patients. Anesthesiology 67:1013–1016,
1987.
14.
Shin B, Mackenzie C, Helrich M: Creatinine clearance
for early detection of posttraumatic renal dysfunction. Anesthesiology 64:605–609,
1986.
15.
Wesson LG, Lauler DP: Diurnal cycle of glomerular
filtration rate and sodium and chloride excretion during responses to altered salt
and water balance in man. J Clin Invest 40:1967–1977, 1961.
16.
Kim KE, Onesti G, Ramirez O, et al: Creatinine
clearance in renal disease. A reappraisal. BMJ 4:11–14, 1969.
17.
Moran SM, Myers BD: Course of acute renal failure
studied by a model of creatinine kinetics. Kidney Int 27:928–937, 1985.
18.
Doolan PD, Alpen EL, Theil GB: A clinical appraisal
of the plasma concentration and endogenous clearance of creatinine. Am J Med 32:65–81,
1962.
19.
Myers BD, Miller DC, Mehigan JT, et al: Nature
of the renal injury following total renal ischemia in man. J Clin Invest 73:329–341,
1984.
20.
Cockroft DW, Gault MH: Prediction of creatinine
clearance from serum creatinine. Nephron 16:31–41, 1976.
21.
Robert S, Zarowitz BJ, Peterson EL, Dumler F:
Predictability of creatinine clearance estimates in the critically ill. Crit Care
Med 21:1487–1495, 1993.
22.
Stanton BA, Koeppen BM: Control of body fluid
osmolality and volume. In Berne RM, Levy MN (eds):
Physiology, 4th ed. St Louis, CV Mosby, 1998, pp 715–743.
23.
Bryan AG, Bolsin SN, Vianna PTG, Haloush H: Modification
of the diuretic and natriuretic effects of a dopamine infusion by fluid loading in
preoperative cardiac surgical patients. J Cardiothorac Vasc Anesth 9:158–163,
1995.
24.
Schaer GL, Fink MP, Parrillo JE: Norepinephrine
alone versus norepinephrine plus low-dose dopamine: Enhanced renal blood flow with
combination pressor therapy. Crit Care Med 13:492–496, 1985.
25.
Haywood GA, Tighe D, Moss R, et al: Goal directed
therapy with dobutamine in a porcine model of septic shock: Effects on systemic
and renal oxygen transport. Postgrad Med J 67(Suppl 1):S36, 1991.
26.
Aronson S, Wiencek JG, Feinstein SB, et al: Assessment
of renal blood flow with contrast ultrasonography. Anesth Analg 76:964, 1993.
27.
Thorburn GD, Kopald HH, Herd JA, et al: Intrarenal
distribution of nutrient blood flow determined by krypton-85 in the unanesthetized
dog. Circ Res 13:290–307, 1963.
28.
Hollenberg NK, Epstein M, Rosen SM, et al: Acute
oliguric failure in man: Evidence for preferential renal cortical ischemia. Medicine
(Baltimore) 47:455–474, 1968.
29.
Aukland K: Methods for measuring renal blood flow:
Total flow and regional distribution. Annu Rev Physiol 42:543–555, 1980.
30.
Priano LL: Effects of anesthetic agents on renal
function. In Barash PG (ed): Refresher Courses
in Anesthesiology. Philadelphia, JB Lippincott, 1985, pp 143–156.
31.
Schrier RW: Effects of the adrenergic nervous
system and catecholamines on systemic and renal hemodynamics, sodium and water excretion
and renin secretion. Kidney Int 6:291–306, 1974.
32.
Levens NR, Peach MJ, Carey RM: Role of the intrarenal
renin-angiotensin system in the control of renal function. Circ Res 48:157–167,
1981.
33.
Ballerman BJ, Zeidel ML, Gunning ME, Brenner BM:
Vasoactive peptides and the kidney. In Brenner
BM, Rector FCJ (eds): The Kidney, 4th ed. Philadelphia, WB Saunders, 1991, pp 510–583.
34.
Hricik D, Browning P, Kopelman R, et al: Captopril-induced
functional renal insufficiency in patients with bilateral renalartery stenoses or
renal-artery stenosis in a solitary kidney. N Engl J Med 308:373–376, 1983.
35.
Wynckel A, Ebikili B, Melin JP, et al: Long-term
follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors.
Am J Hypertens 11:1080–1086, 1998.
36.
Colson P, Ribstein J, Mimran A, et al: Effect
of angiotensin converting enzyme inhibition on blood pressure and renal function
during open heart surgery. Anesthesiology 72:23–27, 1990.
37.
Genuth SM: The adrenal glands. In
Berne RM, Levy MN (eds): Physiology, 4th ed. St Louis, CV Mosby, 1998, pp 930–964.
38.
Baylis PH: Posterior pituitary function in health
and disease. Clin Endocrinol Metab 12:747–770, 1983.
39.
Bartter FC, Schwartz WB: The syndrome of inappropriate
secretion of antidiuretic hormone. Am J Med 42:790–806, 1967.
40.
Edwards RM, Trizna W, Kinter LB: Renal microvascular
effects of vasopressin and vasopressin antagonists. Am J Physiol 256:F274–F278,
1989.
41.
Levenson DJ, Simmons CEJ, Brenner BM: Arachidonic
acid metabolites, prostaglandins and the kidney. Am J Med 72:354–374, 1982.
42.
Johnston PA, Bernard DB, Perrin NS, et al: Prostaglandins
mediate the vasodilatory effect of mannitol in the hypoperfused rat kidney. J Clin
Invest 68:127–133, 1981.
43.
Gerber JG, Olsen RD, Nies AS: Interrelationship
between prostaglandins and renin release. Kidney Int 19:816–821, 1981.
44.
Cumming AD: Acute renal failure and sepsis: Therapeutic
approaches. Nephrol Dial Transplant 4:159–163, 1994.
45.
Nasjletti A, Malik KU: Renal kinin-prostaglandin
relationship: Implications for renal function. Kidney Int 19:860–868, 1981.
46.
Gorfinkel HJ, Szidon JP, Hirsch LJ, et al: Renal
performance in experimental cardiogenic shock. Am J Physiol 222:1260–1268,
1972.
47.
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg
H: A rapid and potent natriuretic response to intravenous injection of atrial myocardial
extract in rats. Life Sci 28:89–94, 1981.
48.
Laragh J: Atrial natriuretic hormone, the renin-angiotensin
axis, and blood-pressure electrolyte homeostasis. N Engl J Med 313:1330–1340,
1985.
49.
Allaqaband S, Tumuluri R, Malik AM, et al: Prospective
randomized study of N-acetylcysteine, fenoldopam,
and saline for prevention of radiocontrast-induced nephropathy. Cathet Cardiovasc
Interv 57:279–283, 2002.
50.
Maack T, Camargo MJF, Kleinert HD, et al: Atrial
natriuretic factor: Structure and functional properties. Kidney Int 27:607–615,
1985.
51.
Shannon RP, Libby E, Elahi D, et al: Impact of
acute reduction in chronically elevated left atrial pressure on sodium and water
excretion. Ann Thorac Surg 46:430–437, 1988.
52.
Goldberg L, Rajfer S: Dopamine receptors: Applications
in clinical cardiology. Circulation 72:245–248, 1985.
53.
Bello-Reuss E, Higashi Y, Kaneda Y: Dopamine decreases
fluid reabsorption in the straight portions of the rabbit proximal tubule. Am J
Physiol 242:F634–F640, 1982.
54.
Olsen NV: Effects of dopamine on renal haemodynamics,
tubular function, and sodium excretion in normal humans. Dan Med Bull 45:282–297,
1998.
55.
Eklof AC: The natriuretic response to a dopamine
DA1 agonist requires endogenous activation of dopamine DA2 receptors. Acta Physiol
Scand 160:311–314, 1997.
56.
Holtbäck U, Kruse MS, Brismar H, Aperia A:
Intrarenal dopamine coordinates the effect of antinatriuretic and natriuretic factors.
Acta Physiol Scand 168:215–218, 2000.
57.
Kuchel O, Buu NT, Unger T: Dopamine sodium relationship:
Is dopamine part of the endogenous natriuretic system? Contrib Nephrol 13:27, 1978.
58.
Steudel W, Hurford WE, Zapol WM: Inhaled nitric
oxide: Basic biology and clinical applications. Anesthesiology 91:1090–1121,
1999.
59.
Ito S, Carretero OA, Abe K: Nitric oxide in the
regulation of renal blood flow. New Horizons 3:615–623, 1995.
60.
Lieberthal W: Biology of ischemic and toxic renal
tubular cell injury: Role of nitric oxide and the inflammatory response. Curr Opin
Nephrol Hypertens 7:289–295, 1998.
61.
Landin L, Lorente JA, Renes E, et al: Inhibition
of nitric oxide synthesis improves the vasoconstrictive effect of noradrenaline in
sepsis. Chest 106:250–256, 1994.
62.
Goligorsky MS, Noiri E: Duality of nitric oxide
in acute renal injury. Semin Nephrol 19:263–271, 1999.
63.
Noiri E, Peresleni T, Miller F, Goligorsky MS:
In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat
kidney against ischemia. J Clin Invest 97:2377–2383, 1996.
64.
Fozard JR, Hannon JP: Adenosine receptor ligands:
Potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther 12:111–114,
1999.
65.
Lee HT, Emala CW: Protective effects of renal
ischemic preconditioning and adenosine pretreatment: Role of A(1) and A(3) receptors.
Am J Physiol Renal Physiol 278:F380–F387, 2000.
66.
Lee HT, Emala CW: Systemic adenosine given after
ischemia protects renal function via A(2a) adenosine receptor activation. Am J Kidney
Dis 38:610–618, 2001.
67.
Armstrong DK, Dasta JF, Reilley TF, Tallman RDJ:
Effect of haloperidol on dopamine-induced increase in renal blood flow. Drug Intell
Clin Pharmacol 20:543–546, 1986.
68.
Hughes A, Thom S, Martin G, et al: The action
of a dopamine (DA1) receptor agonist, fenoldopam, in human vasculature in vivo and
in vitro. Br J Clin Pharmacol 22:535–540, 1986.
69.
Olsen NV, Olsen MH, Bonde J, et al: Dopamine natriuresis
in salt-repleted, water-loaded humans: A dose-response study. Br J Clin Pharmacol
43:509–520, 1997.
70.
Hilberman M, Maseda J, Stinson E, et al: The diuretic
properties of dopamine in patients after open-heart operation. Anesthesiology 61:489–494,
1984.
71.
MacGregor DA, Smith TE, Prielipp RC, et al: Pharmacokinetics
of dopamine in healthy male subjects. Anesthesiology 92:338–346, 2000.
72.
Pass L, Eberhart R, Brown J, et al: The effect
of mannitol and dopamine on the renal response to thoracic aortic cross-clamping.
J Thorac Cardiovasc Surg 95:608–612, 1988.
73.
Ter Wee PM, Smit AJ, Rosman JB, et al: Effect
of intravenous infusion of low-dose dopamine on renal function in normal individuals
and in patients with renal disease. Am J Nephrol 6:42–46, 1986.
74.
Swygert TH, Roberts LC, Valek TR, et al: Effect
of intraoperative low-dose dopamine on renal function in liver transplant recipients.
Anesthesiology 75:571–576, 1991.
75.
Grundmann R, Kindler J, Meider G, et al: Dopamine
treatment of human cadaver kidney graft recipients: A prospectively randomized trial.
Lancet 2:827–828, 1980.
76.
Olsen NV, Lund J, Jensen PF, et al: Dopamine,
dobutamine, and dopexamine. A comparison of renal effects in unanesthetized human
volunteers. Anesthesiology 79:685–694, 1993.
77.
Ghosh S, Gray B, Oduro A, Latimer R: Dopexamine
hydrochloride: Pharmacology and use in low cardiac output states. J Cardiothorac
Vasc Anesth 5:382–389, 1991.
78.
Murphy MB, Murray CB, Shorten GD: Fenoldopam—a
selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.
N Engl J Med 345:1548–1557, 2001.
79.
Singer I, Epstein M: Potential of dopamine A-1
agonists in the management of acute renal failure. Am J Kidney Dis 31:743–755,
1998.
80.
Tobimatsu M, Konomi K, Saito S, Tsumagari T: Protective
effect of prostaglandin E1
on ischemia-induced acute renal failure in
dogs. Surgery 98:45–52, 1985.
81.
Neumayer HH, Gellert J, Luft FC: Calcium antagonists
and renal protection. Ren Fail 15:353–358, 1993.
82.
Diamond J, Cheung J, Fang L: Nifedipine-induced
renal dysfunction. Am J Med 77:905–909, 1984.
83.
Bauer J, Sunderrajan S, Reams G: Effects of calcium
entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics,
salt and water excretion and body fluid composition. Am J Cardiol 56:62H–67H,
1985.
84.
Conger JD, Falk SA, Hammond WS: Atrial natriuretic
peptide and dopamine in established acute renal failure in the rat. Kidney Int 40:21–28,
1991.
85.
Seki G, Suzuki K, Nonaka T, et al: Effects of
atrial natriuretic peptide on glycerol induced acute renal failure in the rat. Jpn
Heart J 33:383–393, 1992.
86.
Rahman SN, Kim GE, Mathew AS, et al: Effects of
atrial natriuretic peptide in clinical acute renal failure. Kidney Int 45:1731–1738,
1994.
87.
Allgren RL, Marbury TC, Rahman SN, et al: Anaritide
in acute tubular necrosis. N Engl J Med 336:828–834, 1997.
88.
Lewis J, Salem MM, Chertow GM, et al: Atrial natriuretic
factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group.
Am J Kidney Dis 36:767–774, 2000.
89.
Kennedy W, Sawyer T, Gerbershagen H, et al: Simultaneous
systemic cardiovascular and renal haemodynamic measurements during high spinal anaesthesia
in normal man. Acta Anaesthesiol Scand 37:163–171, 1970.
90.
Silvarjan M, Amory D, Lindbloom L, et al: Systemic
and regional blood flow changes during spinal anesthesia in the rhesus monkey. Anesthesiology
43:78–88, 1975.
91.
Ecoffey C, Edouard A, Pruszczynski W, et al: Effects
of epidural anesthesia on catecholamines, renin activity and vasopressin changes
induced by tilt in elderly men. Anesthesiology 62:294–297, 1985.
92.
Lunn J, Dannemiller FJ, Stanley TH: Cardiovascular
responses to clamping of the aorta during epidural and general anesthesia. Anesth
Analg 58:372–376, 1979.
93.
Gamulin Z, Forster A, Simonet F, et al: Effects
of renal sympathetic blockade on renal hemodynamics in patients undergoing major
aortic abdominal surgery. Anesthesiology 65:688–692, 1986.
94.
Gelman S, Gowler KC, Smith LR: Regional blood
flow during isoflurane and halothane anesthesia. Anesth Analg 63:557–565,
1984.
95.
Stanley TH, Berman L, Green O, et al: Plasma catecholamine
responses to fentanyl-oxygen anesthesia for coronary artery operation. Anesthesiology
53:250–253, 1980.
96.
Priano LL: Alteration of renal hemodynamics by
thiopental, diazepam and ketamine in conscious dogs. Anesth Analg 61:853–862,
1982.
97.
Mazze RI, Trudell JR, Cousins MJ: Methoxyflurane
metabolism and renal dysfunction: Clinical correlation in man. Anesthesiology 35:247,
1971.
98.
Cousins MJ, Mazze RI: Methoxyflurane nephrotoxicity:
A study of dose response in man. JAMA 225:1611–1616, 1973.
99.
Mazze RI, Cousins MJ, Barr GA: Renal effects and
metabolism of isoflurane in man. Anesthesiology 40:536–542, 1974.
100.
Eger EI 2nd, Koblin DD, Bowland T, et al: Nephrotoxicity
of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 84:160–168,
1997.
101.
Eger EI, Gong D, Koblin DD, et al: Dose-related
biochemical markers of renal injury after sevoflurane versus desflurane anesthesia
in volunteers. Anesth Analg 85:1154–1163, 1997.
102.
Bito H, Ikeuchi Y, Ikeda K: Effects of low-flow
sevoflurane anesthesia on renal function. Anesthesiology 86:1231–1237, 1997.
103.
Kharasch ED, Frink EJJ, Zager R, et al: Assessment
of low-flow sevoflurane and isoflurane effects on renal function using sensitive
markers of tubular toxicity. Anesthesiology 86:1238–1253, 1997.
104.
Ebert TJ, Frink EJ, Kharasch ED: Absence of biochemical
evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar
concentration sevoflurane anesthesia in volunteers. Anesthesiology 88:601–610,
1998.
105.
Doherty D, Sladen RN: Effects of positive airway
pressure on renal function. In Lumb PL (ed): Postoperative
Mechanical Ventilation. Philadelphia, JP Lippincott, 1990, pp 369–386.
106.
Jardin F, Forest JC, Boisante L, et al: Influence
of positive end-expiratory pressure on left ventricular performance. N Engl J Med
304:387–392, 1981.
107.
Sladen A, Laver MB, Pontoppidan H: Pulmonary
complications and water retention in prolonged mechanical ventilation. N Engl J
Med 279:448–453, 1968.
108.
Annat G, Viale JP, Xuan BB, et al: Effect of
PEEP ventilation on renal function, plasma renin, aldosterone, neurophysins and urinary
ADH, and prostaglandins. Anesthesiology 58:136–141, 1983.
109.
Venus B, Mathru M, Smith RA, et al: Renal function
during application of positive end-expiratory pressure in swine: Effects of hydration.
Anesthesiology 62:765–769, 1985.
110.
Hemmer M, Suter PM: Treatment of cardiac and
renal effects of PEEP with dopamine in patients with acute respiratory failure.
Anesthesiology 50:399–403, 1979.
111.
Thompson GE, Miller RD, Stevens WC, et al: Hypotensive
anesthesia for total hip arthroplasty: A study of blood loss and organ function,
brain, heart, liver and kidneys. Anesthesiology 48:91–96, 1978.
112.
Colley PS, Silvarjan M: Regional blood flow in
dogs during halothane anesthesia and controlled hypotension produced by nitroprusside
or nitroglycerin. Anesth Analg 63:503–510, 1984.
113.
Aronson S, Goldberg LI, Glock D, et al: Effects
of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia.
J Cardiothorac Vasc Anesth 5:29–32, 1991.
114.
Myers BD, Moran SM: Hemodynamically mediated
acute renal failure. N Engl J Med 314:97–105, 1986.
115.
Gamulin Z, Forster A, Morel D, et al: Effects
of infra-renal aortic cross-clamping on renal hemodynamics in humans. Anesthesiology
61:394–399, 1984.
116.
Barry K, Cohen A, Knochel J, et al: Mannitol
infusion. II. The prevention of acute functional renal failure during resection
of an aneurysm of the abdominal aorta. N Engl J Med 264:967–971, 1961.
117.
Burke TJ, Cronin RE, Duchin KL, et al: Ischemia
and tubule obstruction during acute renal failure in dogs: Mannitol in protection.
Am J Physiol 238:F305–F314, 1980.
118.
Paul MD, Mazer CD, Byrick RJ, et al: Influence
of mannitol and dopamine on renal function during elective infrarenal aortic cross-clamping
in man. Am J Nephrol 6:427–434, 1986.
119.
Ip-Yam PC, Murphy S, Baines M, et al: Renal function
and proteinuria after cardiopulmonary bypass: The effects of temperature and mannitol.
Anesth Analg 78:842–847, 1994.
120.
Canivet JL, Larbuisson R, Damas P, et al: Plasma
renin activity and urine beta 2-microglobulin during and after cardiopulmonary bypass:
Pulsatile vs non-pulsatile perfusion. Eur Heart J 11:1079–1082, 1990.
121.
Badner NH, Murkin JM, Lok P: Differences in pH
management and pulsatile/nonpulsatile perfusion during cardiopulmonary bypass do
not influence renal function. Anesth Analg 75:696–701, 1992.
122.
Matsuda H, Hirose H, Nakano S, et al: Results
of open heart surgery in patients with impaired renal function as creatinine clearance
below 30 ml/min. The effects of pulsatile perfusion. J Cardiovasc Surg (Torino)
27:595–599, 1986.
123.
Hilberman M, Myers B, Carrie G, et al: Acute
renal failure following cardiac surgery. J Thorac Cardiovasc Surg 77:880–888,
1979.
124.
Hilberman M, Derby GC, Spencer RJ, et al: Sequential
pathophysiological changes characterizing the progression from renal dysfunction
to acute renal failure following cardiac operation. J Thorac Cardiovasc Surg 79:838–844,
1980.
125.
Higgins TL, Estafanous FG, Loop FD, et al: Stratification
of morbidity and mortality outcome by preoperative risk factors in coronary artery
bypass patients. A clinical severity score. JAMA 267:2344–2348, 1992.
126.
Myles PS, Buckland MR, Schenk NJ, et al: Effect
of "renal-dose" dopamine on renal function following cardiac surgery. Anesth Intensive
Care 21:56–61, 1993.
127.
Costa P, Ottino GM, Matani A, et al: Low-dose
dopamine during cardiopulmonary bypass in patients with renal dysfunction. J Cardiothorac
Anesth 4:469–473, 1990.
128.
Chiolero R, Borgeta A, Fisher A: Postoperative
arrhythmias and risk factors after open heart surgery. Thorac Cardiovasc Surg 39:81–84,
1991.
129.
Wardle N: Acute renal failure in the 1980s:
The importance of septic shock and of endotoxemia. Nephron 30:193–200, 1982.
130.
Zager RA: Endotoxemia, renal hypoperfusion, and
fever: Interactive risk factors for aminoglycoside and sepsis-associated acute renal
failure. Am J Kidney Dis 20:223–230, 1992.
131.
Wetzels JF, Burke TJ, Schrier RW: Prevention
and attenuation of acute renal failure. Curr Opin Nephrol Hypertens 1:133–140,
1992.
132.
Clive D, Stoff J: Renal syndromes associated
with nonsteroidal antiinflammatory drugs. N Engl J Med 310:563–572, 1984.
133.
Kunzendorf U, Walz G, Brockmoeller J, et al:
Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine
in kidney graft recipients. Transplantation 52:280–284, 1991.
134.
Neumayer HH, Kunzendorf U, Schreiber M: Protective
effects of calcium antagonists in human renal transplantation. Kidney Int Suppl
36:87–93, 1992.
135.
Parfrey PS, Griffiths SM, Barrett BJ, et al:
Contrast material-induced renal failure in patients with diabetes mellitus, renal
insufficiency or both. A prospective, controlled study. N Engl J Med 320:143, 1989.
136.
Eisenberg RL, Bank WO, Hedgecock MW: Renal failure
after major angiography can be avoided with hydration. Am J Radiol 136:859, 1981.
137.
Tepel M, van der Giet M, Schwarzfeld C, et al:
Prevention of radiographic-contrast-agent-induced reductions in renal function by
acetylcysteine. N Engl J Med 343:180–184, 2000.
138.
Briguori C, Manganelli F, Scarpato P, et al:
Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40:298–303,
2002.
139.
Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam
mesylate blocks reductions in renal plasma flow after radio-contrast dye infusion:
A pilot trial in the prevention of contrast nephropathy. Am Heart J 143:894–903,
2002.
140.
Gabow PA, Kaehny WD, Kelleher SP: The spectrum
of rhabdomyolysis. Medicine (Baltimore) 61:141, 1982.
141.
Clyne DH, Kant KS, Pesce AJ, Pollack VE: Nephrotoxicity
of low molecular weight serum proteins. Physicochemical interactions between myoglobin,
hemoglobin, Bence-Jones protein and Tamm-Horsfall mucoprotein. Curr Probl Clin Biochem
9:299, 1979.
142.
Ellinas PA, Rosner F: Rhabdomyolysis: Report
of eleven cases. JAMA 84:617–624, 1992.
143.
Ron D, Taitelman U, Michaelson M, et al: Prevention
of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 144:277, 1984.
144.
Wait RB, Kahng KU: Renal failure complicating
obstructive jaundice. Am J Surg 157:256–263, 1989.
145.
Plusa SM, Clark NW: Prevention of postoperative
renal dysfunction in patients with obstructive jaundice: A comparison of mannitol-induced
diuresis and oral sodium taurocholate. J R Coll Surg Edinb 36:303–305, 1991.
146.
Gubern JM, Martinez-Rodenas F, Sitges-Serra A:
Use of mannitol as a measure to prevent postoperative renal failure in patients
with obstructive jaundice [letter]. Am J Surg 159:444–445, 1990; comment.
147.
Zager RA: Sepsis-associated acute renal failure:
Some potential pathogenetic and therapeutic insights. Nephrol Dial Transplant 4:164–167,
1994.
148.
Cumming AD, Driedger AA, McDonald JW, et al:
Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11:23–32,
1988.
149.
Badr KF: Sepsis-associated renal vasoconstriction:
Potential targets for future therapy. Am J Kidney Dis 20:207–213, 1992.
150.
Cumming AD, McDonald JW, Lindsay RM, et al: The
protective effect of thromboxane synthetase inhibition on renal function in systemic
sepsis. Am J Kidney Dis 13:114–119, 1989.
151.
Garella S, Matarese RA: Renal effects of prostaglandins
and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine
(Baltimore) 63:165–181, 1984.
152.
Bone RC, Fisher CJ, Clemmer TP, et al: A controlled
clinical trial of high-dose methylprednisolone in the treatment of severe sepsis
and septic shock. N Engl J Med 317:653–658, 1987.
153.
Effect of high-dose glucocorticoid therapy on
mortality in patients with clinical signs of systemic sepsis. The Veterans Administration
Systemic Sepsis Cooperative Study Group. N Engl J Med 317:659–665, 1987.
154.
Slotman GJ, Fisher CJJ, Bone RC, et al: Detrimental
effects of high-dose methylprednisolone sodium succinate on serum concentrations
of hepatic and renal function indicators in severe sepsis and septic shock. The
Methylprednisolone Severe Sepsis Study Group. Crit Care Med 21:191–195, 1993.
155.
Rudis MI, Basha MA, Zarowitz BJ: Is it time to
reposition vasopressors and inotropes in sepsis? Crit Care Med 24:525–537,
1996.
156.
Weber A, Schwieger IM, Poinsot O, et al: Sequential
changes in renal oxygen consumption and sodium transport during hyperdynamic sepsis
in sheep. Am J Physiol 262(Pt 2):F965, 1992.
157.
Bersten AD, Rutten AJ: Renovascular interaction
of epinephrine, dopamine, and intraperitoneal sepsis. Crit Care Med 23:537–544,
1995.
158.
Lherm T, Troche G, Rossignol M, et al: Renal
effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated
with catecholamines. Intensive Care Med 22:213–219, 1996.
159.
Bellomo R, Chapman M, Finfer S, et al: Low-dose
dopamine in patients with early renal dysfunction: A placebo-controlled randomised
trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials
Group. Lancet 356:2139–2143, 2000.
160.
Smithies M, Yee TH, Jackson L, et al: Protecting
the gut and the liver in the critically ill: Effects of dopexamine. Crit Care Med
22:789–795, 1994.
161.
Hesselvik JF, Brodin B: Low-dose norepinephrine
in patients with septic shock and oliguria: Effects on afterload, urine flow and
oxygen transport. Crit Care Med 17:179–180, 1989.
162.
Landry DW, Oliver JA: The pathogenesis of vasodilatory
shock. N Engl J Med 345:588–595, 2001.
163.
Argenziano M, Choudri AF, Oz MC, et al: A prospective
randomized trial of arginine vasopressin in the treatment of vasodilatory shock after
left ventricular assist device placement. Circulation 96(9 Suppl):II-286–II-290,
1997.
164.
Landry DW, Levin HR, Gallant EM, et al: Vasopressin
deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125,
1997.
165.
Landry DW, Levin HR, Gallant EM, et al: Vasopressin
pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282,
1997.
